A substantial number of clinical reports have shown that patients with kinase‐activating lesions associated with BCR‐ABL1‐like ALL are amenable to targeted therapy, with tyrosine kinase inhibitors for patients with ABL‐class fusions, and JAK inhibitors for those with JAK2 fusions or mutations.26, 27, 28, 29, 30. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.